Global Markets Direct’s, 'Overactive Bladder - Pipeline Review, H1
2012', provides an overview of the Overactive Bladder therapeutic
pipeline. This report provides information on the therapeutic
development for Overactive Bladder, complete with latest updates, and
special features on late-stage and discontinued projects. It also
reviews key players involved in the therapeutic development for
Overactive Bladder. 'Overactive Bladder - Pipeline Review, H1 2012' is
built using data and information sourced from Global Markets Direct’s
proprietary databases, Company/University websites, SEC filings,
investor presentations and featured press releases from
company/university sites and industry-specific third party sources, put
together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Overactive Bladder.
- A review of the Overactive Bladder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Overactive Bladder pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Overactive Bladder.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Overactive Bladder pipeline depth and focus of Overactive Bladder therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Overactive Bladder – Pipeline Review H1 2012
Published: March 2012 No. of Pages: 101
Price: Single User: US $ 500 Corporate User: US $ 1500
Table of Contents
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Overactive Bladder Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Overactive Bladder 11
Overactive Bladder Therapeutics under Development by Companies 13
Overactive Bladder Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Discovery and Pre-Clinical Stage Products 20
Comparative Analysis 20
Overactive Bladder Therapeutics – Products under Development by Companies 21
Overactive Bladder Therapeutics – Products under Investigation by Universities/Institutes 22
Companies Involved in Overactive Bladder Therapeutics Development 23
Allergan, Inc. 23
Merck & Co., Inc. 24
Dainippon Sumitomo Pharma Co., Ltd. 25
Takeda Pharmaceutical Company Limited 26
American Oriental Bioengineering, Inc. 27
Astellas Pharma Inc. 28
Auxilium Pharmaceuticals, Inc. 29
Recordati S.p.A. 30
Teva Pharmaceutical Industries Limited 31
Addex Pharmaceuticals 32
Hisamitsu Pharmaceutical Co., Inc. 33
Urigen Pharmaceuticals, Inc. 34
Plethora Solutions Holdings plc 35
KeyNeurotek Pharmaceuticals AG 36
PharmEste 37
Pear Tree Pharmaceuticals 38
Hydra Biosciences, Inc. 39
Mt Cook Pharma. Inc. 40
Overactive Bladder – Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Combination Products 42
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
SMP-986 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
YM905 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Betanis - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
AA4010 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
REC 0422 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
REC 1819 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
PSD506 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
URG302 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
XEN-D0501 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
KN203 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
MK-4618 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Botox - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Botox - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Botox - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
MCP-202 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
AGN-214868 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
MCP-101 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
AOBO-001 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
THVD-201 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Bryophyllum Pinnatum - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
DR-3001 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
HC-067047 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
REC 0436 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
TRPs antagonists - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Second Generation Of TRPV1 Antagonists - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Liposome Encapsulated Botulinum Toxin A - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Tolterodine + Tamsulosin - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
TD9594 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
THVD-101a - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
THVD-202 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Targeted Toxin - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
HOB-294 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
GABA-BR PAM - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
TAK-259 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Diltiazem - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Overactive Bladder Therapeutics – Drug Profile Updates 88
Overactive Bladder Therapeutics – Discontinued Products 92
Overactive Bladder Therapeutics - Dormant Products 93
Overactive Bladder – Product Development Milestones 94
Featured News & Press Releases 94
Dec 08, 2011: Antares's Oxybutynin Gel Product Receives FDA Approval For Treatment Of Overactive Bladder 94
Nov 23, 2011: Provesica Publishes XEN-D0501 Phase I Data On Innovative New Medicine For Overactive Bladder 94
Nov 11, 2011: Astellas Announces Receipt Of Filing Communication Letter From FDA Regarding Mirabegron 95
Aug 29, 2011: Astellas Pharma Announces Regulatory Submissions For Mirabegron For Overactive Bladder In US And Europe 95
Jul 01, 2011: Astellas Receives Approval For Betanis Tablet In Japan For Overactive Bladder 96
May 16, 2011: TheraVida Initiates Phase II Trial Of THVD-201 For Overactive Bladder And Urinary Incontinence 96
Apr 20, 2011: Astellas Launches Orally Disintegrating Vesicare OD Tablet In Japan 97
Apr 05, 2011: Ono Pharmaceutical Launches Orally Disintegrating Tablet Of Staybla Tablets 0.1mg For Overactive Bladder 97
Mar 22, 2011: TheraVida Announces Positive Results From Phase I Trial Of THVD-201 98
Mar 21, 2011: Astellas Announces Encouraging Results From Phase III Study of Mirabegron In OAB 99
Appendix 100
Methodology 100
Coverage 100
Secondary Research 100
Primary Research 100
Expert Panel Validation 100
Contact Us 101
Disclaimer 10
List of Tables
List of Figures
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Overactive Bladder.
- A review of the Overactive Bladder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Overactive Bladder pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Overactive Bladder.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Overactive Bladder pipeline depth and focus of Overactive Bladder therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Overactive Bladder – Pipeline Review H1 2012
Published: March 2012 No. of Pages: 101
Price: Single User: US $ 500 Corporate User: US $ 1500
Table of Contents
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Overactive Bladder Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Overactive Bladder 11
Overactive Bladder Therapeutics under Development by Companies 13
Overactive Bladder Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Discovery and Pre-Clinical Stage Products 20
Comparative Analysis 20
Overactive Bladder Therapeutics – Products under Development by Companies 21
Overactive Bladder Therapeutics – Products under Investigation by Universities/Institutes 22
Companies Involved in Overactive Bladder Therapeutics Development 23
Allergan, Inc. 23
Merck & Co., Inc. 24
Dainippon Sumitomo Pharma Co., Ltd. 25
Takeda Pharmaceutical Company Limited 26
American Oriental Bioengineering, Inc. 27
Astellas Pharma Inc. 28
Auxilium Pharmaceuticals, Inc. 29
Recordati S.p.A. 30
Teva Pharmaceutical Industries Limited 31
Addex Pharmaceuticals 32
Hisamitsu Pharmaceutical Co., Inc. 33
Urigen Pharmaceuticals, Inc. 34
Plethora Solutions Holdings plc 35
KeyNeurotek Pharmaceuticals AG 36
PharmEste 37
Pear Tree Pharmaceuticals 38
Hydra Biosciences, Inc. 39
Mt Cook Pharma. Inc. 40
Overactive Bladder – Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Combination Products 42
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
SMP-986 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
YM905 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Betanis - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
AA4010 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
REC 0422 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
REC 1819 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
PSD506 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
URG302 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
XEN-D0501 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
KN203 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
MK-4618 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Botox - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Botox - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Botox - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
MCP-202 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
AGN-214868 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
MCP-101 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
AOBO-001 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
THVD-201 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Bryophyllum Pinnatum - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
DR-3001 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
HC-067047 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
REC 0436 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
TRPs antagonists - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Second Generation Of TRPV1 Antagonists - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Liposome Encapsulated Botulinum Toxin A - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Tolterodine + Tamsulosin - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
TD9594 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
THVD-101a - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
THVD-202 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Targeted Toxin - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
HOB-294 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
GABA-BR PAM - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
TAK-259 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Diltiazem - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Overactive Bladder Therapeutics – Drug Profile Updates 88
Overactive Bladder Therapeutics – Discontinued Products 92
Overactive Bladder Therapeutics - Dormant Products 93
Overactive Bladder – Product Development Milestones 94
Featured News & Press Releases 94
Dec 08, 2011: Antares's Oxybutynin Gel Product Receives FDA Approval For Treatment Of Overactive Bladder 94
Nov 23, 2011: Provesica Publishes XEN-D0501 Phase I Data On Innovative New Medicine For Overactive Bladder 94
Nov 11, 2011: Astellas Announces Receipt Of Filing Communication Letter From FDA Regarding Mirabegron 95
Aug 29, 2011: Astellas Pharma Announces Regulatory Submissions For Mirabegron For Overactive Bladder In US And Europe 95
Jul 01, 2011: Astellas Receives Approval For Betanis Tablet In Japan For Overactive Bladder 96
May 16, 2011: TheraVida Initiates Phase II Trial Of THVD-201 For Overactive Bladder And Urinary Incontinence 96
Apr 20, 2011: Astellas Launches Orally Disintegrating Vesicare OD Tablet In Japan 97
Apr 05, 2011: Ono Pharmaceutical Launches Orally Disintegrating Tablet Of Staybla Tablets 0.1mg For Overactive Bladder 97
Mar 22, 2011: TheraVida Announces Positive Results From Phase I Trial Of THVD-201 98
Mar 21, 2011: Astellas Announces Encouraging Results From Phase III Study of Mirabegron In OAB 99
Appendix 100
Methodology 100
Coverage 100
Secondary Research 100
Primary Research 100
Expert Panel Validation 100
Contact Us 101
Disclaimer 10
List of Tables
List of Figures
No comments:
Post a Comment